Impact of Final Activated Clotting Time After Transradial Coronary Stenting With Maximal Antiplatelet Therapy

American Journal of Cardiology

Volumn 104, Issue 9, 2009, Pages 1235-1240

  Bertrand, Olivier F ^a   Rodés Cabau, Josep ^a   Rinfret, Stéphane ^a   Larose, Éric ^a   Bagur, Rodrigo ^a   Proulx, Guy ^a   Gleeton, Onil ^a   Costerousse, Olivier ^a   De Larochellière, Robert ^a   Roy, Louis ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CREATINE KINASE MB; HEPARIN; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BLOOD VESSEL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEATH; DRUG FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE NECROSIS; HEART PROTECTION; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SIDE EFFECT; TARGET VESSEL REVASCULARIZATION; THROMBOCYTOPENIA; TRANSRADIAL CORONARY STENTING;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; FEMALE; FOLLOW-UP STUDIES; HEMATOMA; HEMORRHAGE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PREMEDICATION; RETREATMENT; SEX FACTORS; STENTS; TICLOPIDINE; TROPONIN T; WHOLE BLOOD COAGULATION TIME;

EID: 71749109424     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.036     Document Type: Article

References (24)

1. Bertrand O.F., De Larochelliere R., Rodes-Cabau J., Proulx G., Gleeton O., Nguyen C.M., Dery J.P., Barbeau G., Noel B., Larose E., Poirier P., and Roy L. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 114 (2006) 2636-2643
2. Bertrand O.F., Rodes-Cabau J., Larose E., Nguyen C.M., Roy L., Dery J.P., Courtis J., Nault I., Poirier P., Costerousse O., and De Larochelliere R. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) study. Am Heart J 156 (2008) 135-1340
3. Bertrand O.F., Rodes-Cabau J., Larose E., Proulx G., Gleeton O., Nguyen C.M., Nault I., Roy L., Poirier P., Costerousse O., and De Larochelliere R. Early and late outcomes in patients excluded from same-day home discharge after transradial stenting and maximal antiplatelet therapy. Catheter Cardiovasc Interv 72 (2008) 619-625
4. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., Keren G., Carr J., Cohen E.A., Betriu A., Desmet W., Kereiakes D.J., Rutsch W., Wilcox R.G., De Feyter P.J., Vahanian A., and Topol E.J. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
5. Bertrand O.F., Larose E., Rodes-Cabau J., Gleeton O., Taillon I., Roy L., Poirier P., Costerousse O., and Larochelliere R.D. Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. Am Heart J 157 (2009) 164-169
6. Silber S., Albertsson P., Aviles F.F., Camici P.G., Colombo A., Hamm C., Jorgensen E., Marco J., Nordrehaug J.E., Ruzyllo W., Urban P., Stone G.W., Wijns W., and The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 26 (2005) 804-847
7. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., Morrison D.A., O'Neil W.W., Schaff H.V., Whitlow P.L., Williams D.O., Antman E.M., Adams C.D., Anderson J.L., Faxon D.P., Fuster V., Halperin J.L., Hiratzka L.F., Hunt S.A., Nishimura R., Ornato J.P., Page R.L., and Riegel B. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
8. Ashby D.T., Dangas G., Aymong E.A., Farkouh M.E., Mehran R., Lansky A.J., Moses J.W., Leon M.B., and Stone G.W. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. Am J Cardiol 92 (2003) 319-322
9. Brener S.J., Bhatt D.L., Moliterno D.J., Schneider J.P., Ellis S.G., and Topol E.J. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Am J Cardiol 92 (2003) 1468-1471
10. Hillegass W.B., Brott B.C., Chapman G.D., Phillips H.R., Stack R.S., Tcheng J.E., and Califf R.M. Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. Am Heart J 144 (2002) 501-507
11. Tolleson T.R., O'Shea J.C., Bittl J.A., Hillegass W.B., Williams K.A., Levine G., Harrington R.A., and Tcheng J.E. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 41 (2003) 386-393
12. Narins C.R., Hillegass Jr. W.B., Nelson C.L., Tcheng J.E., Harrington R.A., Phillips H.R., Stack R.S., and Califf R.M. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 93 (1996) 667-671
13. Brener S.J., Moliterno D.J., Lincoff A.M., Steinhubl S.R., Wolski K.E., and Topol E.J. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 110 (2004) 994-998
14. Blankenship J.C., Balog C., Sapp S.K., Califf R.M., Lincoff A.M., Tcheng J.E., and Topol E.J. Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. Catheter Cardiovasc Interv 57 (2002) 476-483
15. Chew D.P., Bhatt D.L., Lincoff A.M., Moliterno D.J., Brener S.J., Wolski K.E., and Topol E.J. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 103 (2001) 961-966
16. Popma J.J., Satler L.F., Pichard A.D., Kent K.M., Campbell A., Chuang Y.C., Clark C., Merritt A.J., Bucher T.A., and Leon M.B. Vascular complications after balloon and new device angioplasty. Circulation 88 (1993) 1569-1578
17. Abdelmeguid A.E., and Topol E.J. The myth of the myocardial "infarctlet" during percutaneous coronary revascularization procedures. Circulation 94 (1996) 3369-3375
18. Califf R.M., Abdelmeguid A.E., Kuntz R.E., Popma J.J., Davidson C.J., Cohen E.A., Kleiman N.S., Mahaffey K.W., Topol E.J., Pepine C.J., Lipicky R.J., Granger C.B., Harrington R.A., Tardiff B.E., Crenshaw B.S., Bauman R.P., Zuckerman B.D., Chaitman B.R., Bittl J.A., and Ohman E.M. Myonecrosis after revascularization procedures. J Am Coll Cardiol 31 (1998) 241-251
19. Harrington R.A., Lincoff A.M., Califf R.M., Holmes Jr. D.R., Berdan L.G., O'Hanesian M.A., Keeler G.P., Garratt K.N., Ohman E.M., Mark D.B., Jacobs A.K., and Topol E.J. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 25 (1995) 1693-1699
20. Nienhuis M.B., Ottervanger J.P., Bilo H.J., Dikkeschei B.D., and Zijlstra F. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 71 (2008) 318-324
21. Saucedo J.F., Mehran R., Dangas G., Hong M.K., Lansky A., Kent K.M., Satler L.F., Pichard A.D., Stone G.W., and Leon M.B. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 35 (2000) 1134-1141
22. Kini A., Kini S., Marmur J.D., Bertea T., Dangas G., Cocke T.P., and Sharma S.K. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv 48 (1999) 123-129
23. Mehran R., Dangas G., Mintz G.S., Lansky A.J., Pichard A.D., Satler L.F., Kent K.M., Stone G.W., and Leon M.B. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation 101 (2000) 604-610
24. Casserly I.P., Topol E.J., Jia G., Lange R.A., Hamm C., Meier B., DiBattiste P.M., Lakkis N., Chew D.P., Stone G.W., Cohen D.J., and Moliterno D.J. Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes-observations from the TARGET trial. Am J Cardiol 92 (2003) 125-129